Monday, February 8, 2016

12:27 PM

UPDRS

International Parkinson and movement Disorder Society

The objective and mission of the Society shall be to:

* + Advance the neurological sciences pertaining to Movement Disorders
  + Improve the diagnosis and treatment of patients; to operate exclusively for scientific, scholarly and educational purposes
  + Encourage research; to provide forums, such as medical journals, scientific symposia and International Congresses
  + Share ideas and to advance the related clinical and scientific disciplines
  + Encourage interest and participation in the activities of the Society among healthcare and allied professionals and scientists
  + Collaborate with other related professional and lay organizations

From <<http://www.movementdisorders.org/MDS/About/Who-We-Are/Purpose-Mission--Goals.htm>>

Parkinson’s disease (PD) is the most common neurodegenerative cause of parkinsonism, a clinical syndrome characterized by lesions in the basal ganglia, predominantly in the substantia nigra. PD makes up approximately 80% of cases of parkinsonism.

As a rule, PD begins between the ages of 40 and 70 years, with peak age onset in the seventh decade.

 The prevalence of PD is approximately 160 cases per 100,000 population, and the incidence is about 20 cases per 100,000 population.

The pathological changes of PD may appear as early as three decades before the appearance of clinical signs.

The cause of PD is probably multifactorial, with contributions from hereditary predisposition, environmental toxins, and aging.

Several studies have indicated that PD is more common among relatives of index cases. When all studies are analyzed, first degree relatives of probands are two to three times more likely to develop PD

The cardinal motor signs and symptoms of PD, include the characteristic clinical picture of resting tremor, rigidity, akinesia, and impairment of postural reflexes.

It evolves slowly.

**Although preclinical detection of PD have been investigated, a practical, inexpensive, sensitive and specific screening test has yet to be made available.**

Before the introduction of levodopa, PD caused severe disability in 16% of patients within five years of onset, in 37% during the next five years, and in 42% of those surviving for 15 years.

The introduction of **levodopa** has been considered one of the success stories of modern medicine.

It remains the most effecacious drug available for the relief of symptoms in PD since its first introduction in the 1960s.

Currently the most popular techniques are:

pallidotomy,

chronic deep-brain stimulation (DBS) of the subthalamic nucleus (STN)

and globus pallidus internus (Gpi) using an implantable pulse generator (IPG)

Parkinsonism

The defining feature of parkinsonism is bradykinesia, or slowness with decrement and degradation of repetitive movements (“fatigue”).

Subtle “bradykinesia” has been reported to occur in the “normal elderly” population, but this may reflect a non-specific slowness rather than bradykinesia as defined above.

**Parkinson’s disease is the most common neurodegenerative cause of parkinsonism.**

**Other causes include multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration.**

These other neurodegenerative conditions are sometimes grouped together under term of “atypical parkinsonism” or “parkinson-plus syndromes”

They do not respond as well to  dopaminergic treatments and generally have a worse prognosis compared to typical Parkinson’s disease.

Degenerative causes of parkinsonism may be difficult to diagnose in the earliest stages and ancillary investigations may be of limited value in this instance.

Parkinsonism can also be symptomatic, as a result of various vascular, drug-related, infectious, toxic, structural and other known secondary causes

From <<http://www.movementdisorders.org/MDS/About/Movement-Disorder-Overviews/Parkinsons-Disease--Parkinsonism.htm>>


**Welcome to the MDS Video Library**

From <<http://www.movementdisorders.org/MDS/Resources/Videos/Video-Library.htm>>

MDS-Recommended Rating Scales

From <<http://www.movementdisorders.org/MDS/Education/Rating-Scales/MDS-Recommended-Rating-Scales.htm>>

Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders



2/8/2016 5:47 PM - Screen Clipping

**Other more recent related work by top paper** 2013

**Biomarkers of Parkinson's disease: Present and future**

From <<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721253/>>

[Surgical Treatment of Parkinson's Disease: A Clinical Prospective Study with Six Years Follow up.](http://search.ebscohost.com/login.aspx?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=16816579&AN=112267904&h=PIC4FQrdzO9Jl2gJK%2BI1sw8pHqBf0pW98fP02Gi9iy0woRIpHEYoByQgkbvVdC1nm8n8jYN94MWy6oSz%2F0GnGA%3D%3D&crl=c)

From <<https://scholar.google.com/scholar?start=10&hl=en&as_sdt=80005&sciodt=0,11&as_ylo=2015&cites=16959047630667096789&scipsc=>>

[A comparative kinematic analysis of cyclical bending in patients with early stages of Parkinson's disease and in patients with essential tremor.](http://search.ebscohost.com/login.aspx?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=10871640&AN=98992696&h=2138RPqnzezJGocXh4o3wSWXsT95WhTIBliIbFTZRs4rPZ%2FqJ0D9IjAUk9lKC9g4Eet0MNZIgDDXn9CX7ViR%2BQ%3D%3D&crl=c)

From <<https://scholar.google.com/scholar?hl=en&as_sdt=80005&sciodt=0%2C11&cites=16959047630667096789&scipsc=&as_ylo=2014&as_yhi=2014>>